195 related articles for article (PubMed ID: 9662595)
41. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
[TBL] [Abstract][Full Text] [Related]
42. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
[TBL] [Abstract][Full Text] [Related]
43. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL.
Jerusalem GH; Beguin YP
Clin Lymphoma; 2002 Jun; 3(1):56-61. PubMed ID: 12141957
[TBL] [Abstract][Full Text] [Related]
44. [Positron emission tomography with 18F-FDG compared with proliferative activity of tumor cells in different subtypes of non-Hodgkin lymphoma].
Tiutin LA; Khodzsibekova MM; Pozharisskiĭ KM; Mukhina MS; Kostenikov NA; Il'in NV
Vopr Onkol; 2011; 57(6):748-52. PubMed ID: 22416392
[TBL] [Abstract][Full Text] [Related]
45. Correlation of 4'-[methyl-(11)C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with (11)C-methionine uptake.
Tanaka K; Yamamoto Y; Maeda Y; Yamamoto H; Kudomi N; Kawai N; Toyohara J; Nishiyama Y
Ann Nucl Med; 2016 Feb; 30(2):89-96. PubMed ID: 26511019
[TBL] [Abstract][Full Text] [Related]
46. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.
Karam M; Novak L; Cyriac J; Ali A; Nazeer T; Nugent F
Cancer; 2006 Jul; 107(1):175-83. PubMed ID: 16721817
[TBL] [Abstract][Full Text] [Related]
47. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.
Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Lorenz WJ; Maier-Borst W; van Kaick G
Eur J Nucl Med; 1995 May; 22(5):434-42. PubMed ID: 7641752
[TBL] [Abstract][Full Text] [Related]
49. Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma.
Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L
Curr Probl Diagn Radiol; 2006; 35(4):151-63. PubMed ID: 16814002
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma.
Manohar K; Mittal BR; Bhattacharya A; Malhotra P; Varma S
Nucl Med Commun; 2012 Sep; 33(9):974-81. PubMed ID: 22811258
[TBL] [Abstract][Full Text] [Related]
51. 18F-FDG PET in children with lymphomas.
Depas G; De Barsy C; Jerusalem G; Hoyoux C; Dresse MF; Fassotte MF; Paquet N; Foidart J; Rigo P; Hustinx R
Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):31-8. PubMed ID: 15605288
[TBL] [Abstract][Full Text] [Related]
52. Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for evaluating the clinicopathological grade in patients with non-Hodgkin's lymphoma: a prospective study.
Shinya T; Otomi Y; Dimitrakopoulou-Strauss A; Kubo M; Kondo M; Otomo M; Terazawa K; Bando Y; Harada M
Nucl Med Commun; 2020 Jan; 41(1):26-33. PubMed ID: 31800508
[TBL] [Abstract][Full Text] [Related]
53. Comparison of gallium-67-citrate and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma.
Waxman AD; Eller D; Ashook G; Ramanna L; Brachman M; Heifetz L; McAndrews P; Bierman H; Taub R; Avedo M; Wall F
J Nucl Med; 1996 Jan; 37(1):46-50. PubMed ID: 8544000
[TBL] [Abstract][Full Text] [Related]
54. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography.
Martiat P; Ferrant A; Labar D; Cogneau M; Bol A; Michel C; Michaux JL; Sokal G
J Nucl Med; 1988 Oct; 29(10):1633-7. PubMed ID: 3262725
[TBL] [Abstract][Full Text] [Related]
55. Lymphography for staging lymphomas: is it still a useful procedure?
North LB; Wallace S; Lindell MM; Jing BS; Fuller LM; Allen PK
AJR Am J Roentgenol; 1993 Oct; 161(4):867-9. PubMed ID: 8372776
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
57. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma.
Schiepers C; Filmont JE; Czernin J
Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S82-8. PubMed ID: 12719922
[TBL] [Abstract][Full Text] [Related]
58. Biologic progression in non-Hodgkin's lymphoma. A flow cytometric study.
Joensuu H; Klemi PJ; Jalkanen S
Cancer; 1990 Jun; 65(11):2564-71. PubMed ID: 2337874
[TBL] [Abstract][Full Text] [Related]
59. The impact of FDG positron emission tomography imaging on the management of lymphomas.
Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
[TBL] [Abstract][Full Text] [Related]
60. Prognostic value of FDG-PET in malignant lymphoma.
Becherer A; Jaeger U; Szabo M; Kletter K
Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
